![Jean Bizzari](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jean Bizzari
Directeur/Membre du Conseil chez
ADC THERAPEUTICS SA
Fortune : 474 560 $ au 31/05/2026
Profil
Dr. Jean P.
Bizzari, MD, is an Independent Director at Aprea Therapeutics, Inc., an Independent Non-Executive Director at ADC Therapeutics SA, a Chairman at NETRIS Pharma SAS and a President & Director at Synergie Lyon Cancer.
He is on the Board of Directors at Aprea Therapeutics, Inc., ADC Therapeutics SA, European Organisation for Research & Treatment of Cancer, Oxford BioTherapeutics Ltd., International Drug Development Institute SA and Synergie Lyon Cancer.
Dr. Bizzari was previously employed as an Independent Director by Nordic Nanovector ASA, an Independent Director by Valerio Therapeutics SA, an Independent Director by Pieris Pharmaceuticals, Inc., an Independent Director by Celator Pharmaceuticals, Inc., an Independent Director by Halozyme Therapeutics, Inc., an Executive Vice President & Global Head-Oncology by Celgene Corp., an Independent Director by Transgene SA, a Vice President-Clinical Oncology Development by Sanofi-Aventis Pharmaceuticals, a Vice President-Clinical Development Oncology by Sanofi-Synthelabo, Inc., a Vice President-Clinical Development Oncology by Rhone Poulenc Rorer, a Vice President-Clinical Oncology by Rhône-Poulenc, Inc., a Head-Oncology by Institut de Recherches Internationales Servier, and a Vice President-Clinical Development by Aventis, Inc. He also served on the board at Compugen Ltd., Theravectys SAS and iTeos Therapeutics SA. He received his graduate degree from the University of Nice Sophia Antipolis and a doctorate degree from the University of Nice Sophia Antipolis.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ADC THERAPEUTICS LTD 0,11% | 03/06/2026 | 139 302 ( 0,11% ) | 473 627 $ | 31/05/2026 |
| 16/06/2026 | 1 045 ( 0,01% ) | 933 $ | 31/05/2026 |
Postes actifs de Jean Bizzari
| Sociétés | Poste | Début |
|---|---|---|
| ADC THERAPEUTICS SA | Directeur/Membre du Conseil | 01/06/2022 |
| APREA THERAPEUTICS, INC. | Directeur/Membre du Conseil | 23/08/2023 |
NETRIS Pharma SAS
 NETRIS Pharma SAS BiotechnologyHealth Technology Develops targeted therapies for the treatment of cancer | Président | - |
International Drug Development Institute SA
 International Drug Development Institute SA Miscellaneous Commercial ServicesCommercial Services Provides biostatistics and e-Clinical solutions for phase I-IV clinical trials | Directeur/Membre du Conseil | - |
Synergie Lyon Cancer
 Synergie Lyon Cancer Miscellaneous Commercial ServicesCommercial Services Engages in research and development in therapeutic approaches | President | - |
Oxford BioTherapeutics Ltd.
 Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops antibody-based medicines for oncology | Directeur/Membre du Conseil | 16/12/2016 |
European Organisation for Research & Treatment of Cancer
 European Organisation for Research & Treatment of Cancer Miscellaneous Commercial ServicesCommercial Services Operates as non-profit cancer research organization | Directeur/Membre du Conseil | - |
Anciens postes connus de Jean Bizzari
| Sociétés | Poste | Fin |
|---|---|---|
| HALOZYME THERAPEUTICS, INC. | Directeur/Membre du Conseil | 25/04/2024 |
| COMPUGEN LTD. | Directeur/Membre du Conseil | 01/03/2022 |
| ░░░░░░ ░░░░░░░░░░░░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Jean Bizzari
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
62
Relations au 1er degré
24
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 24 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Develops cancer and immunology drugs | Health Technology |
Compugen Ltd.
 Compugen Ltd. BiotechnologyHealth Technology Discovers and researches drug & diagnostics | Health Technology |
Halozyme Therapeutics, Inc.
 Halozyme Therapeutics, Inc. BiotechnologyHealth Technology Engages in the development and commercialization of recombinant human enzymes for the infertility, ophthalmology & oncology markets | Health Technology |
Transgene SA
 Transgene SA BiotechnologyHealth Technology Designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer | Health Technology |
Aventis, Inc.
 Aventis, Inc. MiscellaneousMiscellaneous Functions as an investment holding company | Miscellaneous |
Celator Pharmaceuticals, Inc.
 Celator Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs to treat acute myeloid leukemia and AML with myelodysplasia in children & adults | Health Technology |
Oxford BioTherapeutics Ltd.
Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops antibody-based medicines for oncology | Health Technology |
Valerio Therapeutics SA
 Valerio Therapeutics SA Pharmaceuticals: MajorHealth Technology Develops drugs for the treatment of cancer | Health Technology |
Rhone Poulenc Rorer
 Rhone Poulenc Rorer Chemicals: SpecialtyProcess Industries Manufactures and distributs pharmaceutical products. | Process Industries |
University of Nice Sophia Antipolis
 University of Nice Sophia Antipolis Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sanofi-Synthelabo, Inc. | Health Technology |
Rhône-Poulenc, Inc. | Process Industries |
Sanofi-Aventis Pharmaceuticals | |
Synergie Lyon Cancer
Synergie Lyon Cancer Miscellaneous Commercial ServicesCommercial Services Engages in research and development in therapeutic approaches | Commercial Services |
European Organisation for Research & Treatment of Cancer
European Organisation for Research & Treatment of Cancer Miscellaneous Commercial ServicesCommercial Services Operates as non-profit cancer research organization | Commercial Services |
International Drug Development Institute SA
International Drug Development Institute SA Miscellaneous Commercial ServicesCommercial Services Provides biostatistics and e-Clinical solutions for phase I-IV clinical trials | Commercial Services |
Nordic Nanovector ASA
 Nordic Nanovector ASA Pharmaceuticals: MajorHealth Technology Develops innovative anticancer therapeutics | Health Technology |
ADC Therapeutics SA
 ADC Therapeutics SA Pharmaceuticals: MajorHealth Technology Develops proprietary antibody drug conjugates for the treatment of both solid and hematological cancers | Health Technology |
Theravectys SAS
 Theravectys SAS BiotechnologyHealth Technology Provides biotechnology research services | Health Technology |
iTeos Therapeutics SA
 iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology Engages in the discovery of immunomodulators for cancer therapy | Health Technology |
Pieris Pharmaceuticals, Inc.
 Pieris Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops and markets an anticalin-brand protein technology | Health Technology |
Institut de Recherches Internationales Servier
 Institut de Recherches Internationales Servier Miscellaneous Commercial ServicesCommercial Services Provides scientific research & development services | Commercial Services |
NETRIS Pharma SAS
NETRIS Pharma SAS BiotechnologyHealth Technology Develops targeted therapies for the treatment of cancer | Health Technology |
Aprea Therapeutics, Inc.
 Aprea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as biopharmaceutical company which develops novel anticancer compounds | Health Technology |
